150 related articles for article (PubMed ID: 25120665)
1. Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.
Peng YH; Xu YW; Qiu SQ; Hong CQ; Zhai TT; Li EM; Xu LY
Oncol Lett; 2014 Sep; 8(3):1096-1102. PubMed ID: 25120665
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
[TBL] [Abstract][Full Text] [Related]
3. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
4. Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma.
Lin LH; Xu YW; Huang LS; Hong CQ; Zhai TT; Liao LD; Lin WJ; Xu LY; Zhang K; Li EM; Peng YH
Clin Proteomics; 2017; 14():6. PubMed ID: 28184180
[TBL] [Abstract][Full Text] [Related]
5. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
9. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies.
Chen Y; Xin X; Cui Z; Zheng Y; Guo J; Chen Y; Lin Y; Su G
Clin Lab; 2016; 62(6):1155-66. PubMed ID: 27468579
[TBL] [Abstract][Full Text] [Related]
12. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
15. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
16. A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study.
Rao D; Fu M; Chen Y; Liu Q; Xiao L; Zhang X; Li Z; Li H; He Y; Chen Y; Chen J; Hu J; Huang Y
PeerJ; 2020; 8():e10254. PubMed ID: 33240616
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis.
Li S; Deng Y; Li X; Chen QP; Liao XC; Qin X
Chin Med J (Engl); 2010 May; 123(9):1201-5. PubMed ID: 20529563
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
19. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
Shimakage M; Dezawa T; Chatani M
Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
[TBL] [Abstract][Full Text] [Related]
20. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]